You are here

Retrospective Evaluation of the Radiographic Efficacy of Conventional and Biologic Treatment

Last updated on November 21, 2019

FOR MORE INFORMATION
Study Location
Schmittingheide 20-32, Munster, 48155 Denmark
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Secure diagnosis of rheumatoid arthritis

- Older than 18 years

- Two consecutive plain radiographs of the hands and feet with a time interval of 12 to
36 months are available. The radiographs are recorded 2003 or later and are in
accordance with a defined X-ray protocol.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients who receive Anakinra, Rituximab or Abatacept

NCT00929357
Pfizer
Completed
Retrospective Evaluation of the Radiographic Efficacy of Conventional and Biologic Treatment

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Rheumatoid Arthritis
NCT03981900
All Genders
18+
Years
Multiple Sites
Rheumatoid Arthritis, Psoriatic Arthritis
NCT02984020
All Genders
19+
Years
Multiple Sites
Descriptive Information
Brief TitleRetrospective Evaluation of the Radiographic Efficacy of Conventional and Biologic Treatment
Official TitleA Retrospective Evaluation of the Radiographic Efficacy of Different Conventional Systemic Therapies and Biologics in Patients With Rheumatoid Arthritis in Routine Practice.
Brief SummaryThis study involves review and analysis of disease activity in patients with rheumatoid arthritis who where treated with either conventional DMARDs (Disease Modifying Antirheumatic Drugs) or Biologics and have two existing, consecutive radiographs (x-ray images) of hand and feet taken as part of routine treatment monitoring within a time interval of 12 to 36 months.
Detailed DescriptionNot Provided
Study TypeObservational
Study DesignObservational Model: Cohort
Time Perspective: Retrospective
Target Follow-Up DurationNot Provided
BiospecimenNot Provided
Sampling MethodNon-Probability Sample
Study Population200
ConditionRheumatoid Arthritis
InterventionDrug: DMARDs or Biologics
Study Groups/Cohorts
  • 1
    DMARDs
    Intervention: Drug: DMARDs or Biologics
  • 2
    Biologics
    Intervention: Drug: DMARDs or Biologics
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment StatusCompleted
Actual Enrollment
 (submitted: June 6, 2011)
156
Original Estimated Enrollment
 (submitted: June 25, 2009)
200
Actual Study Completion DateJune 2010
Actual Primary Completion DateJune 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Secure diagnosis of rheumatoid arthritis
  • Older than 18 years
  • Two consecutive plain radiographs of the hands and feet with a time interval of 12 to 36 months are available. The radiographs are recorded 2003 or later and are in accordance with a defined X-ray protocol.

Exclusion Criteria:

- Patients who receive Anakinra, Rituximab or Abatacept

Sex/Gender
Sexes Eligible for Study:All
Ages18 Years and older   (Adult, Older Adult)
Accepts Healthy VolunteersNo
ContactsContact information is only displayed when the study is recruiting subjects
Listed Location CountriesDenmark
Removed Location Countries  
 
Administrative Information
NCT NumberNCT00929357
Other Study ID Numbers0881X1-4617
Has Data Monitoring CommitteeNot Provided
U.S. FDA-regulated ProductNot Provided
IPD Sharing StatementNot Provided
Responsible PartyDirector, Clinical Trial Disclosure Group, Wyeth
Study SponsorPfizer
CollaboratorsNot Provided
Investigators
Study Director:Pfizer CT.gov Call CenterWyeth is now a wholly owned subsidiary of Pfizer
PRS AccountPfizer
Verification DateAugust 2011

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now